Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease

Share Article

New data presented by genetic testing company Proove Biosciences on genetics and hypertensive heart disease.

"This study is an important first step towards addressing individual genetic risk factors for hypertensive heart disease" - Maggie Hopkins, Clinical Science Liaison at Proove Biosciences

Proove Biosciences, a commercial and research leader in Personalized Medicine, recently presented new data on the relationship of genetics and hypertension at the International Academy of Cardiology Annual Scientific Sessions 2015 20th World Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview of the latest research developments in cardiovascular medicine, took place on July 25th - 27th at the Hyatt Regency Vancouver.

An oral presentation on Genetics and Heart Disease: Study on the Relationship Between 5HT2a and Hypertensive Heart Disease was delivered on July 26th, 2015. The objective of the Genetics and Hypertension study is to determine whether or not a link exists between genetics and hypertension. According to the CDC, hypertension, or high-blood pressure, affects over 70 million American adults and is considered to be the leading cause of death in the US. While it is widely understood that high-blood pressure is heavily influenced by lifestyle choices, little is known about the influence of genetics on heart disease.

Proove Biosciences’ researchers analyzed the genetic information from 42 subjects with hypertensive heart disease and compared it to that of 43 healthy control subjects. Results of the Genetics and Heart Disease: Study on the Relationship Between 5HT2A and Hypertensive Heart Disease found that certain variations in the Serotonin Receptor gene were associated with hypertensive heart disease, and that gender adds to the risk as well. Researchers hope to use this data to develop an algorithm that will inform physicians whether their patients are genetically high-risk for hypertensive heart disease.

There is a mixed range of evidence for how to treat hypertension, mostly based on age,” said Maggie Hopkins, Clinical Science Liaison at Proove Biosciences. “Guidelines do not take into account gender, or individual risk predispositions; although several studies have outlined response differentials between females and males treated with hypertensives. This study is an important first step towards addressing individual genetic risk factors for hypertensive heart disease.”

About Proove Biosciences
Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Hana Greenwood
Proove Biosciences
+1 855-776-6832 Ext: 1522
Email >
@proovebio
Follow >
Proove Biosciences, Inc.
since: 02/2012
Like >
Proove Biosciences, Inc.

Visit website